MADISON, Wis.--(BUSINESS WIRE)--The Baylor College of Medicine Human Genome Sequencing Center (BCM-HGSC) has standardized its target enrichment human disease research studies on Roche NimbleGen (SIX: RO, ROG; OTCQX: RHHBY) Sequence Capture Exome technology. The Baylor HGSC will sequence over 5,000 exomes in the next two years to identify genetic variants underlying multiple human diseases and will employ NimbleGen SeqCap EZ Exome and customized NimbleGen exome designs as the exome capture technology of choice. More than 15 different diseases will be investigated by Baylor HGSC, including brain, liver, pancreatic, colon, ovarian and bladder cancers, heart disease, diabetes, autism, and other inherited diseases with the goal of better understanding causative mutations and their impact on these diseases. These studies are supported by multiple funds from the National Institutes of Health (NIH) and other research consortia. Through collaboration with Roche NimbleGen, BCM- HGSC has established and optimized their pipeline for high throughput exome capture and sequencing with multiple next-generation sequencing platforms. Baylor has already captured and sequenced over 2,000 samples, with roughly 1,000 of these using exome sequencing.
